In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Valeant buys Xcel for $280mm

Executive Summary

To expand its North American neurology business, Valeant Pharmaceuticals International (neurology, dermatology, and infectious disease therapeutics) has agreed to acquire privately held Xcel Pharmaceuticals, a biotech company specializing in CNS drugs, for $280mm in cash, which includes the assumption of $44mm in debt.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register